Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics
Advertisement
Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications.
This collaboration combines the strengths of both companies' technologies to develop a next generation immunotherapeutic treatment that could provide systemic anti-cancer effect and immunity, with minimal systemic side effects for the benefit of cancer patients.
Dr Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience, commented: "We are very pleased to work with BioInvent, a company with proven success in developing antibody-based drugs, and we believe that Alligator Biosciences technology and know-how will add a substantial value and success to this joint program. Further, it also confirms that Alligator Biosciences technology is valuable and needed for the development of next generation antibody based drugs". According to the terms, the parties will after an initial research phase share costs and revenues equally.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
More than just a kinase: CDK6 in cancer
HLA-DQ
Mutant gut bacteria reverse colon cancer in lab models, UF researchers find
Microbix Biosystems granted U.S. patent for its influenza vaccine yield enhancement technology
Category:Dermatology
Meige's_syndrome

New base at the heart of science and industry - LUMITOS AG now calls Germany's largest science and technology park in Berlin-Adlershof its home
Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia - Investment supports growing demand for biopharmaceutical manufacturing

Stretched beyond the limits - Why playing football can at times be really painful
Category:Immunology
Steve_Wallace_(NASCAR)
